Additional file 1: of Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial

Abstract

Table S1. Serological, virological, and biochemical responses at week 48 by baseline HBeAg-positivity. Table S2. Serological, virological, and biochemical responses at week 48 by status of liver cirrhosis. Table S3. Serological, virological, and biochemical responses at week 48 by gender. Table S4. Characteristics of the patients at virologic breakthrough. (DOCX 51 kb